Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid

References

• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243-9s
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84
   PubMed Web of Science ®Google Scholar
• Major PP, Cook RJ, Chen BL, et al. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2005;2:234-40
   PubMedGoogle Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with different types of cancer. Acta Oncol 2009;48:105-15
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-7
   PubMed Web of Science ®Google Scholar
• Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007;57:229-32
   PubMed Web of Science ®Google Scholar
• Langford DJ, Tripathy D, Paul SM, et al. Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. J Pain 2011;12:495-507
   PubMed Web of Science ®Google Scholar
• Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-32
   PubMed Web of Science ®Google Scholar
• Berenson JR, Rajdev L, Broder M. Treatment strategies for skeletal complications of cancer. Cancer Biol Ther 2006;5:1074-7
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
   PubMed Web of Science ®Google Scholar
• Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57
   PubMed Web of Science ®Google Scholar
• Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009;20:1303-17
   PubMed Web of Science ®Google Scholar
• Zometa (zoledronic acid) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011
   Google Scholar
• Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw 2009;7(Suppl 3):S1-32; quiz S3-5
   PubMedGoogle Scholar
• Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221-7
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Lin SJ, Guo A, et al. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin 2011;27:55-62
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45
   PubMed Web of Science ®Google Scholar
• Body J-J, Cook R, Costa L, et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. In: Proceedings of the IX International Meeting on Cancer Induced Bone Disease; 2009 Oct 28-31. Poster 71
   Google Scholar
• Costa L, Cook R, Body J-J, et al. Zoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption. In: Proceedings of the IX International Meeting on Cancer Induced Bone Disease; 2009 Oct 28-31. Poster 50
   Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-99
   PubMed Web of Science ®Google Scholar
• Budman DR, Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 2006;70:147-53
   PubMed Web of Science ®Google Scholar
• Journe F, Magne N, Chaboteaux C, et al. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clin Exp Metastasis 2006;23:135-47
   PubMed Web of Science ®Google Scholar
• Ottewell PD, Lefley DV, Cross SS, et al. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010;126:522-32
   PubMed Web of Science ®Google Scholar
• Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105
   PubMed Web of Science ®Google Scholar
• Spence MM, Hui RL, Chan J, et al. Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid. Ann Pharmacother 2010;44:1384-8
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87
   PubMed Web of Science ®Google Scholar
• Shah SR, Jean GW, Keisner SV, et al. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid. Support Care Cancer 2012;20:87-93
   PubMed Web of Science ®Google Scholar